Brought to you by 
Paladin buys struggling CNS company Allon Therapeutics for $Cdn900k
24 Aug 2020
Executive Summary
Paladin Labs Inc. (builds its portfolio through in-licensing) has paid $Cdn900k ($866k) in cash to acquire formerly publicly traded Allon Therapeutics Inc. (had been developing CNS candidates). The transaction was conducted as a result of Allon’s proposed bankruptcy filing in Canada, and the company will immediately disperse the funds it receives to its creditors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Paladin buys struggling CNS company Allon Therapeutics for $Cdn900k
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice